Geoffrey M. Parker
CIK 1491874 · CHIEF FINANCIAL OFFICER · last filed 2026-09-15
Geoffrey M. Parker is a CHIEF FINANCIAL OFFICER who has filed 132 SEC Form 4 insider transactions across 9 companies since 2010. The most recent filing, for PRGO, was dated Sep 15, 2026. Across all open-market trades the lifetime net is +$5.8M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.5M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TCDA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MENLO PARK, CA 94025
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRGO | Director | 51,855 | $16.31 | $845.8K | $1.63M | 33 | 2026-09-15 |
| ALLO | CHIEF FINANCIAL OFFICER | 1,252,795 | $1.32 | $1.66M | -$95.3K | 9 | 2026-02-04 |
| Better Therapeutics, Inc. (BTTX) Delisted | Director | 1,085,138 | $0.04 | $48.4K | $917.2K | 9 | 2023-12-20 |
| CCXI | Director | 0 | $10.50 | $0 | -$2.61M | 25 | 2022-10-24 |
| Tricida, Inc. (TCDA) Delisted | COO, CFO and EVP | 118,617 | $0.11 | $12.8K | $4.25M | 17 | 2022-03-02 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 955 | — | — | $0 | 4 | 2019-06-18 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | Director | 385 | $18.62 | $7.2K | $58.2K | 6 | 2017-06-02 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Executive Vice President & CFO | 104,840 | $10.19 | $1.07M | $1.67M | 20 | 2015-03-23 |
| GENOPTIX INC (GXDX) Delisted | Director | 4,167 | — | — | $0 | 4 | 2011-03-01 |
Recent Filings
132 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-15 | PRGO | Mixed | +656 | $9.0K | EDGAR |
| 2026-06-16 | PRGO | Mixed | +507 | $5.6K | EDGAR |
| 2026-05-15 | PRGO | Mixed | +3,798 | $41.2K | EDGAR |
| 2026-03-17 | PRGO | Grant (A) | — | $0 | EDGAR |
| 2026-02-04 | ALLO | Mixed | −24,001 | -$42.2K | EDGAR |
| 2026-02-02 | ALLO | Notice (144) | −24,001 | -$42.2K | EDGAR |
| 2025-12-16 | PRGO | Grant (A) | — | $0 | EDGAR |
| 2025-11-14 | PRGO | Buy (P) | +7,500 | $106.3K | EDGAR |
| 2025-10-23 | ALLO | Sell (S) | −36,744 | -$46.2K | EDGAR |
| 2025-10-21 | ALLO | Notice (144) | −36,744 | -$46.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.